Business Wire

NTTVC Publicly Announces $500 Million Fund Created in Partnership with NTT

Share

NTTVC today publicly announced its $500 million fund to help startups reach rapid global scale by harnessing the power of partnership. The independent venture capital firm was founded by entrepreneur and investor Vab Goel in collaboration with global technology service provider NTT. The firm is also announcing investments in five startups delivering impactful innovations for businesses and consumers: Celona, Eko, nference, Shoreline and UDP Labs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201026005262/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

NTTVC Founding Partner Vab Goel and Partner Fay Hazaveh Costa (Photo: Business Wire)

NTTVC invests broadly across all stages and sectors, with an emphasis on the future of enterprise, digital health and innovations powered by AI, machine learning and data. By combining the deep relationships of its investment team with the reach of NTT, the firm offers access to a robust network of industry experts, customers, entrepreneurs, business leaders, system integrators and service providers who can help startups make better decisions, more quickly.

NTT is a $109 billion, top five global technology service provider serving 75 million mobile subscribers, 3 million businesses and 120,000 enterprise customers with a local presence in over 80 countries. The company has a long history of embracing startups and helping them achieve global scale. By partnering with Goel to form a returns-driven venture capital fund, NTT deepens its commitment to building long-term relationships in the entrepreneurial ecosystem. In turn, NTTVC portfolio companies have the choice and opportunity to sell to, through and with NTT to help scale their businesses.

“Our mission is to use technology for good to solve social challenges for people, clients and communities,” said Jun Sawada, President and CEO of NTT Corporation. “We have always believed that the startup ecosystem is essential to delivering on that promise, which is why we chose to partner with NTTVC to fuel the next generation of world-changing technologies.”

Collectively, the NTTVC team has founded, advised, scaled and invested in over a hundred startups. Their drive for supporting entrepreneurs stems from their direct experiences as founders and venture capitalists. Prior to founding NTTVC, Goel was a Partner at Norwest Venture Partners for 19 years and helped build many of the foundational technologies of today’s Internet as an entrepreneur, venture capitalist and technologist. Partner Fay Hazaveh Costa worked closely with Goel at Norwest Venture Partners and previously helped launch Hewlett Packard Enterprise’s venture group. Mike Koenig, Portfolio Development Partner, is a seasoned sales and business development leader who was an early executive at two startups backed by Goel. Koenig supports NTTVC portfolio companies through impactful connections with the firm’s network.

“We are still in the early innings of a digital transformation that is affecting every industry and creating unprecedented opportunities for startups,” said Vab Goel. “We are passionate about teaming up with entrepreneurs through every phase of their journey to build impactful companies.”

“NTTVC offers entrepreneurs the best of both worlds: an independent and agile investment model coupled with the unique access to our global network,” said Fay Hazaveh Costa. “This powerful combination gives startups a true competitive advantage in scaling and realizing their vision.”

For more information read the firm’s blog post and visit nttvc.com.

About NTTVC

NTTVC is an independent venture capital firm formed in collaboration with NTT. Leveraging a unique partnership-focused strategy and deep industry network, NTTVC unlocks doors to relationships that can help startups reach global scale. With its $500M inaugural fund, the firm invests broadly in technology startups of all stages and sectors, with an emphasis on the future of enterprise, digital health and innovations powered by AI, machine learning and data. NTTVC is headquartered in Silicon Valley. Learn more at nttvc.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Marisa Lam
GMK Communications for NTTVC
marisa@gmkcommunications.com
650.544.3350

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dare to DeFi: DeFi Summit’s First-Ever Global Virtual Conference Brings Together Over 120 Top Industry Leaders14.6.2021 02:15:00 CEST | Press release

The largest-ever dedicated conference focused specifically on decentralized finance starts today at 9am Pacific Time. DeFi Summit is a weeklong virtual event bringing together the builders and developers that make up the decentralized finance and non-fungible token community. Free to attend, talks and presentations will be held on a broad range of topics, including DEX, wallets, DAOs, NFTs, insurance, lending, and many more. DeFi Summit 2021 Agenda: Day 1 (Monday, June 14) – The summit starts with a full day focused on NFTs. Notable speakers include digital artists Pplpleasr and Matty Mo, Max Moore of Sotheby’s, and companies including Axie Infinity, Animoca Brands and Aavegotchi. Day 2 (Tuesday, June 15) – A mystery billionaire investor is the special guestjoining Polygon Power Hour alongside Stani Kulechov from Aave, Sandeep Naiwal from Polygon and Roc Zacharias from Quickswap. Stay tuned for Coinbase, Unicrypt, Finance.Vote, and YFDAI, plus an exciting panel featuring OG DeFi VCs Le

Celltrion Healthcare presents the first real-world data for Truxima ® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress12.6.2021 17:45:00 CEST | Press release

Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1 CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6 This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment t

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® ▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 09:01:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 09:00:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an

Alluzience ® , the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 11:53:00 CEST | Press release

Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As

Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 10:15:00 CEST | Press release

The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,

Luxembourg’s Supercomputer MeluXina is Operational11.6.2021 09:18:00 CEST | Press release

Luxembourg’s high performance computer MeluXina was officially launched on June 7 putting the country on the global map of computer super powers. MeluXina is capable of executing more than 10 Petaflops, the equivalent of 10 million billion calculations per second, which will rank it among the world’s top 50 supercomputers. The petascale computer is powered by green energy and is part-funded under the European High Performance Computing Joint Undertaking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005115/en/ Minister of State Xavier Bettel; His Royal Highness Henri, Grand Duke of Luxembourg; Minister of the Economy Franz Fayot; EuroHPC Joint Undertaking Executive Director Anders Jensen (Photo: Business Wire) In a series of 8 high-performance computers in the EU, MeluXina joins Vega, another petascale supercomputer located in Slovenia, as the first EuroHPC machines to go live. Its innovative modular architecture allo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom